Vaccine against Lawsonia intracellularis and porcine circovirus 2
The present invention pertains to a vaccine comprising in combination killed whole cell Lawsonia intracellularis bacteria and porcine circo virus 2 (PCV2) ORF2 protein for use in protecting a pig against an infection with Lawsonia intracellularis and PCV2 by an intradermal administration of the vaccine. The invention also pertains to a method to protect a swine against an infection with Lawsonia intracellularis bacteria and PCV2.
1. A method to protect a swine against an infection with Lawsonia intracellularis bacteria and porcine circo virus 2 (PCV2), comprising administering into the dermis of the animal a vaccine comprising in combination killed whole cell Lawsonia intracellularis bacteria and PCV2 ORF2 protein; wherein said vaccine comprises less than 12.5% (v/v) mineral oil.
2. The method of claim 1 , that leads to protection after a single shot administration of the vaccine.
3. The method of claim 2 , wherein the vaccine further comprises inactivated Mycoplasma hyopneumoniae (Mhyo) antigens.
4. The method of claim 3 , wherein the inactivated Mycoplasma hyopneumoniae antigens comprise a Mycoplasma hyopneumoniae bacterin.
5. The method of claim 4 , wherein the amount of killed Lawsonia intracellularis bacteria in the vaccine per dose is 1×10 9 .
6. The method of claim 5 , wherein the Lawsonia bacteria are freeze-dried prior to adding the bacteria to a composition to constitute the vaccine.
7. The method of claim 1 , wherein the amount of killed Lawsonia intracellularis bacteria in the vaccine per dose is 1×10 9 .
8. The method of claim 7 , wherein the vaccine further comprises inactivated Mycoplasma hyopneumoniae (Mhyo) antigens.
9. The method of claim 8 , wherein the inactivated Mycoplasma hyopneumoniae antigens comprise a Mycoplasma hyopneumoniae bacterin.
10. The method of claim 9 , wherein the Lawsonia bacteria are freeze-dried prior to adding the bacteria to a composition to constitute the vaccine.
11. A method to protect a swine against an infection with Lawsonia intracellularis bacteria and PCV2, comprising administering into the dermis of the animal a vaccine comprising in combination killed whole cell Lawsonia intracellularis bacteria and porcine circo virus 2 (PCV2) ORF2 protein; wherein said vaccine further comprises an adjuvant comprising an oil-in-water emulsion with less than 12.5% (v/v) mineral oil.
12. The method of claim 11 , that leads to protection after a single shot administration of the vaccine.
13. The method of claim 11 , wherein the amount of killed Lawsonia intracellularis bacteria in the vaccine per dose is 1×10 9 .
14. The method of claim 11 , wherein the vaccine further comprises inactivated Mycoplasma hyopneumoniae (Mhyo) antigens.
15. The method of claim 14 , wherein the inactivated Mycoplasma hyopneumoniae antigens comprise a Mycoplasma hyopneumoniae bacterin.
16. The method of claim 15 , wherein the Lawsonia bacteria are freeze-dried prior to adding the bacteria to a composition to constitute the vaccine.